Schetters H, Hehlmann R, Erfle V, Kreeb G, Rohmer H, Schmidt J
Eur J Cancer Clin Oncol. 1985 Jun;21(6):687-700. doi: 10.1016/0277-5379(85)90266-4.
We have shown previously that antigens and also circulating immune complexes related to the primate retroviral envelope glycoprotein SiSV gp70 correlate with early mortality and survival of 56 patients with acute leukemias and chronic myelogenous leukemia in blast crisis. The prevalence and general distribution of these antigens and immune complexes in human sera was therefore of obvious interest. We now report an analysis of a total of 200 sera from 166 patients. Of these 113 sera were obtained from 84 patients with acute or chronic leukemias and 87 from 82 non-leukemic subjects, including laboratory workers and patients with non-leukemic neoplasias. Antigens and immune complexes were determined by enzyme-linked immunosorbent assays (ELISA). The anti-SiSV gp70 antiserum used predominantly recognized the protein moieties of the glycoproteins. The distribution of SiSV gp70-related antigens and immune complexes was similar among leukemic and non-leukemic sera. The prevalence of SiSV gp70-related antigens was 53% and of SiSV gp70-related immune complexes 49% in all sera. SiSV gp70-related antigens were detected in a somewhat higher proportion of non-leukemic (69%) than leukemic sera (40%), whereas SiSV gp70-related immune complexes and cross-reactive antibodies were more evenly distributed in leukemic and non-leukemic sera (in 46 and 51% of leukemic and 54 and 51% of non-leukemic sera). Presence of antigens correlated with presence of SiSV gp70-related immune complexes in 71% of all sera, but in 13% of all sera antigens were detectable only by determining SiSV gp70-related immune complexes. Total circulating immune complexes did not correlate with SiSV gp70-related immune complexes. The origin and pathophysiological role of the antigens are discussed.
我们之前已经表明,与灵长类逆转录病毒包膜糖蛋白SiSV gp70相关的抗原以及循环免疫复合物与56例急性白血病和慢性粒细胞白血病急变期患者的早期死亡率和生存率相关。因此,这些抗原和免疫复合物在人血清中的患病率和总体分布显然备受关注。我们现在报告对来自166例患者的总共200份血清的分析。其中,113份血清来自84例急性或慢性白血病患者,87份来自82例非白血病受试者,包括实验室工作人员和非白血病性肿瘤患者。通过酶联免疫吸附测定(ELISA)确定抗原和免疫复合物。所使用的抗SiSV gp70抗血清主要识别糖蛋白的蛋白质部分。SiSV gp70相关抗原和免疫复合物在白血病血清和非白血病血清中的分布相似。在所有血清中,SiSV gp70相关抗原的患病率为53%,SiSV gp70相关免疫复合物的患病率为49%。在非白血病血清(69%)中检测到SiSV gp70相关抗原的比例略高于白血病血清(40%),而SiSV gp70相关免疫复合物和交叉反应抗体在白血病血清和非白血病血清中的分布更为均匀(白血病血清中分别为46%和51%,非白血病血清中分别为54%和51%)。在所有血清的71%中,抗原的存在与SiSV gp70相关免疫复合物的存在相关,但在所有血清的13%中,仅通过测定SiSV gp70相关免疫复合物才能检测到抗原。总循环免疫复合物与SiSV gp70相关免疫复合物无关。本文讨论了这些抗原的来源和病理生理作用。